Clinical Trial Update: Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nilotinib 300 mg twice daily in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase patients intolerant to pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Philidelphia Positive Chronic Myeloid Leukaemia | Phase 3 | Status: TERMINATED | Results posted: 2017-10-27